These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32385697)

  • 1. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
    Kim S; Rush BS; Rice TR
    Eur Child Adolesc Psychiatry; 2021 Oct; 30(10):1485-1501. PubMed ID: 32385697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
    Santucci MC; Ansari M; Nikayin S; Radhakrishnan R; Rhee TG; Wilkinson ST
    J Clin Psychiatry; 2024 Oct; 85(4):. PubMed ID: 39361411
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
    Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
    Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
    Kritzer MD; Mischel NA; Young JR; Lai CS; Masand PS; Szabo ST; Mathew SJ
    Ann Clin Psychiatry; 2022 Feb; 34(1):33-43. PubMed ID: 35166663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
    d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
    Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
    Wilkinson ST; Ballard ED; Bloch MH; Mathew SJ; Murrough JW; Feder A; Sos P; Wang G; Zarate CA; Sanacora G
    Am J Psychiatry; 2018 Feb; 175(2):150-158. PubMed ID: 28969441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
    McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
    Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
    Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of adipokines in the rapid antidepressant effects of ketamine.
    Machado-Vieira R; Gold PW; Luckenbaugh DA; Ballard ED; Richards EM; Henter ID; De Sousa RT; Niciu MJ; Yuan P; Zarate CA
    Mol Psychiatry; 2017 Jan; 22(1):127-133. PubMed ID: 27046644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
    Surjan J; Grossi JD; Del Porto JA; Delfino RS; de Oliveira Cerqueira R; Lucchese AC; Magalhães E; Del Sant LC; Tuena MA; Nakahira C; Fava VAR; Steglich MS; Abdo GL; Barbosa MG; Sarin LM; Lacerda ALT
    Clin Drug Investig; 2022 Oct; 42(10):865-873. PubMed ID: 36044154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
    Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
    J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
    Price RB; Iosifescu DV; Murrough JW; Chang LC; Al Jurdi RK; Iqbal SZ; Soleimani L; Charney DS; Foulkes AL; Mathew SJ
    Depress Anxiety; 2014 Apr; 31(4):335-43. PubMed ID: 24668760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions.
    Ryan K; Hosanagar A
    Curr Psychiatry Rep; 2023 Aug; 25(8):337-344. PubMed ID: 37389787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
    J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.